Multiple Doors, One Drug: Navigating the Fragmented GLP-1 Access Landscape

The obesity care ecosystem has fractured into competing access pathways as GLP-1 medications become available through manufacturer direct programs, digital health platforms, retail health clinics, and traditional provider channels simultaneously. Patients can now access the same therapies through Lilly Direct, Hims & Hers, MinuteClinic, telehealth services, or their primary care physician, each pathway offering different pricing, support services, and care models. This fragmentation creates both opportunity and chaos: expanded access for patients previously unable to navigate traditional healthcare, but also care continuity challenges, outcome accountability questions, and confusion about which models actually support sustainable weight management beyond initial prescribing.

This meeting examines how pharmaceutical manufacturers, digital health companies, retail health operators, and traditional healthcare providers are navigating the fragmented GLP-1 landscape, and explores which access models are achieving long-term patient adherence and clinical outcomes versus those optimized for rapid patient acquisition, where partnerships between pharma and different distribution channels create value versus channel conflict, and what this ecosystem evolution means for future specialty medication launches. 

Join us to discuss:

• How are different GLP-1 access pathways performing on patient outcomes, adherence, and satisfaction?

• Where do partnerships between pharmaceutical manufacturers and various distribution channels create genuine value versus fragmenting care and accountability?

• What lessons from the GLP-1 distribution revolution will shape how future high-demand specialty medications reach patients?